{"title":"罕见双侧卵巢混合生殖细胞瘤的诊断与治疗1例。","authors":"Xuanling Li, Min You, Xiaoyun Zhang, Jingjing Wei, Guangyao Lin, Qianjue Tang, Lianwei Xu","doi":"10.3389/fonc.2025.1504231","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Mixed ovarian malignant germ cell tumors (MOGCTs) are rare neoplasms composed of two or more malignant germ cell components, representing less than 1% of all ovarian germ cell tumors. They primarily affect adolescents and young women, presenting a clinical challenge due to their histologic heterogeneity, potential for recurrence, and the need to balance oncologic safety with fertility preservation.</p><p><strong>Case presentation: </strong>We reported a 22-year-old woman diagnosed with a four-component MOGCT in the right ovary-comprising yolk sac tumor, immature teratoma, embryonal carcinoma, and dysgerminoma-along with a dysgerminoma component in the left ovary. Considering her age and fertility desire, fertility-sparing surgery was performed, followed by adjuvant BEP chemotherapy. At 12-month follow-up, the patient remained disease-free with regular menstruation and no signs of recurrence.</p><p><strong>Conclusion: </strong>This case highlights the feasibility of fertility-sparing treatment in patients with complex bilateral MOGCTs. Given the rarity and histological diversity of such tumors, individualized treatment planning, strict staging, and long-term surveillance are essential to optimize clinical outcomes and preserve reproductive potential.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1504231"},"PeriodicalIF":3.5000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463601/pdf/","citationCount":"0","resultStr":"{\"title\":\"Diagnosis and management of a rare bilateral ovarian mixed germ cell tumor: a case report.\",\"authors\":\"Xuanling Li, Min You, Xiaoyun Zhang, Jingjing Wei, Guangyao Lin, Qianjue Tang, Lianwei Xu\",\"doi\":\"10.3389/fonc.2025.1504231\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Mixed ovarian malignant germ cell tumors (MOGCTs) are rare neoplasms composed of two or more malignant germ cell components, representing less than 1% of all ovarian germ cell tumors. They primarily affect adolescents and young women, presenting a clinical challenge due to their histologic heterogeneity, potential for recurrence, and the need to balance oncologic safety with fertility preservation.</p><p><strong>Case presentation: </strong>We reported a 22-year-old woman diagnosed with a four-component MOGCT in the right ovary-comprising yolk sac tumor, immature teratoma, embryonal carcinoma, and dysgerminoma-along with a dysgerminoma component in the left ovary. Considering her age and fertility desire, fertility-sparing surgery was performed, followed by adjuvant BEP chemotherapy. At 12-month follow-up, the patient remained disease-free with regular menstruation and no signs of recurrence.</p><p><strong>Conclusion: </strong>This case highlights the feasibility of fertility-sparing treatment in patients with complex bilateral MOGCTs. Given the rarity and histological diversity of such tumors, individualized treatment planning, strict staging, and long-term surveillance are essential to optimize clinical outcomes and preserve reproductive potential.</p>\",\"PeriodicalId\":12482,\"journal\":{\"name\":\"Frontiers in Oncology\",\"volume\":\"15 \",\"pages\":\"1504231\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463601/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fonc.2025.1504231\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fonc.2025.1504231","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Diagnosis and management of a rare bilateral ovarian mixed germ cell tumor: a case report.
Background: Mixed ovarian malignant germ cell tumors (MOGCTs) are rare neoplasms composed of two or more malignant germ cell components, representing less than 1% of all ovarian germ cell tumors. They primarily affect adolescents and young women, presenting a clinical challenge due to their histologic heterogeneity, potential for recurrence, and the need to balance oncologic safety with fertility preservation.
Case presentation: We reported a 22-year-old woman diagnosed with a four-component MOGCT in the right ovary-comprising yolk sac tumor, immature teratoma, embryonal carcinoma, and dysgerminoma-along with a dysgerminoma component in the left ovary. Considering her age and fertility desire, fertility-sparing surgery was performed, followed by adjuvant BEP chemotherapy. At 12-month follow-up, the patient remained disease-free with regular menstruation and no signs of recurrence.
Conclusion: This case highlights the feasibility of fertility-sparing treatment in patients with complex bilateral MOGCTs. Given the rarity and histological diversity of such tumors, individualized treatment planning, strict staging, and long-term surveillance are essential to optimize clinical outcomes and preserve reproductive potential.
期刊介绍:
Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.